The results of a clinical trial also showed a low to normal level of bone markers after treatment with nilotinib, despite secondary hyperparathyroidism, further revealing the antiresorptive effect of DDR1 inhibition [36]. Here, DDR1 is linked to secondary hyperparathyroidism.